Yoshimi Maekawa Selected Research

KW-2450

1/2018	Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole.
4/2016	Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yoshimi Maekawa Research Topics

Disease

2	Breast Neoplasms (Breast Cancer) 01/2018 - 04/2016
2	Exanthema (Rash) 01/2018 - 04/2016
2	Hyperglycemia 01/2018 - 04/2016
2	Neoplasms (Cancer) 04/2016 - 12/2002
1	Carcinoma (Carcinomatosis) 04/2016
1	Colorectal Neoplasms (Colorectal Cancer) 12/2002

Drug/Important Bio-Agent (IBA)

2	KW-2450IBA 01/2018 - 04/2016
2	Letrozole (Femara)FDA LinkGeneric 01/2018 - 04/2016
2	Lapatinib (GW572016)FDA Link 01/2018 - 04/2016
1	Aromatase (CYP19)IBA 01/2018
1	afimoxifene (hydroxytamoxifen)IBA 01/2018
1	human ERBB2 proteinIBA 01/2018
1	Drug CombinationsIBA 01/2018
1	Hormones (Hormone)IBA 01/2018
1	ErbB Receptors (EGF Receptor)IBA 04/2016
1	Insulin-Like PeptidesIBA 04/2016
1	EnzymesIBA 12/2002
1	Pharmaceutical PreparationsIBA 12/2002
1	diacetylfluorescein (fluorescein diacetate)IBA 12/2002
1	TransferasesIBA 12/2002
1	Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)IBA 12/2002
1	Fluorouracil (Carac)FDA LinkGeneric 12/2002

Therapy/Procedure

1	Therapeutics 04/2016